{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"pt-141-post-surgery","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-post-surgery/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/pt-141-post-surgery/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-post-surgery/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-post-surgery/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-post-surgery/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-post-surgery/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/pt-141-post-surgery/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"pt-141-post-surgery","title":"PT-141 for Post-Surgery: Sexual and CNS Arousal Pathways in Recovery","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:09.189Z","body_excerpt":"## What's breaking down\n\nPost-surgery recovery often involves layers of change that extend beyond the surgical site itself. Nerve disruption, hormonal shifts, reduced mobility, and psychological stress can affect multiple systems. One relevant layer for many patients is sexual function and central nervous system (CNS) arousal pathways. Surgery such as prostate procedures can alter nerve signaling and hormone levels, leading to diminished sexual desire even when physical capacity for orgasm remains. This creates a mismatch where mechanical responses may be addressable but the drive and arousal signals from the brain are reduced. The condition persists when repair processes in these neural and motivational pathways lag behind the degenerative effects of the procedure and recovery period.\n\n## Why PT-141 might help you\n\nPT-141 targets the sexual and CNS arousal layer. If that layer is part of your problem after surgery, PT-141 is discussed because it acts on melanocortin receptors in the hypothalamus to enhance arousal signals at the source in the brain.\n\n1. Therefore for you: If your post-surgery experience includes reduced sexual thoughts or motivation despite preserved physical capability, the CNS-focused action aligns with addressing the arousal pathway directly.\n2. Therefore for you: If conventional approaches focus only on blood flow or local tissue, PT-141 operates upstream in the brain, potentially supporting the motivational component of recovery rather than masking symptoms.\n3. Therefore for you: If nerve or hormonal changes from surgery have dampened desire pathways, activating MC4 receptors may promote dopamine release involved in sexual motivation, fitting a repair-oriented discussion of those specific circuits.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\n\n## What the evidence actually shows\n\nHuman data comes primarily from trials in hypoactive sexual desire disorder (HSDD). Two Phase 3 randomized controlled trials (BMT-301 and BMT-302) enrolled over 1,200 premenopausal women and tested subcutaneous bremelanotide 1.75 mg as-needed versus placebo. These showed statistically significant improvements in sexual desire scores and reduced distress compared to placebo (human tier). A long-term open-label extension followed participants for up to 18 months and reported sustained effects with manageable side effects in completers (human tier). Earlier smaller studies measured physiological arousal via vaginal pulse amplitude after erotic stimuli and found greater increases with bremelanotide than placebo in healthy women and those with arousal disorder (human tier, small n).\n\nNo dedicated human trials specifically examine PT-141 after surgery. Mentions of post-prostatectomy use appear in clinical discussion articles but lack controlled data (anecdotal/mechanistic tier). Animal studies demonstrate melanocortin agonism increasing sexual behaviors in rodents via hypothalamic pathways (preclinical tier). These do not directly model human post-surgical states.\n\nReddit anecdotes describe subjective increases in arousal or desire after injection, with onset in 1-6 hours and variable duration, alongside reports of nausea or flushing (anecdotal tier). X posts echo similar user experiences of heightened motivation but remain self-reported without controls.\n\n## What scientists say\n\nResearchers describe bremelanotide as a nonselective melanocortin receptor agonist with primary action at MC4R in the medial preoptic area of the hypothalamus, leading to increased dopamine release in reward and motivation circuits (mechanistic tier from reviews). This central mechanism differentiates it from peripheral vasodilators. Scientists note the absence of large post-surgical human datasets and emphasize that approved use remains limited to HSDD in premenopausal women.\n\n## What people say on","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"Two Phase 3 RCTs (BMT-301, BMT-302) showed statistically significant improvements in sexual desire scores with bremelanotide 1.75 mg vs placebo in women with HSDD.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the primary human efficacy data tier for the compound's approved indication.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c2","text":"No dedicated randomized human trials examine PT-141 specifically in post-surgical populations.","tier":"human","weight":0.8,"section":"What we do not know","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap for the article's specific context.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c3","text":"Bremelanotide acts as an MC4R agonist in the hypothalamus, increasing dopamine release in motivation circuits.","tier":"mechanistic","weight":0.3,"section":"What scientists say","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Provides the core mechanism explanation tied to the CNS arousal layer.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c4","text":"User reports on Reddit describe subjective arousal increases 1-6 hours after PT-141 injection with variable side effects like nausea.","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Documents real-world anecdotal layer separate from trials.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT01382719","title":"Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder","quote":"This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide...","summary":"Phase 3 trial details supporting HSDD efficacy data.","claim_ids":["c1"],"link_status":"ok","quote_status":"unverified","hash":"b37ba9f623c01df7436e68e9bf724e6497f8f74017b8f526eb5785cf8b6decf7"},{"id":"s2","type":"other","url":"https://www.bostonmedicalgroup.com/pt-141-low-libido-after-prostate-surgery/","title":"Can the PT-141 Peptide Improve Low Libido After Prostate Surgery?","quote":"In this article, we'll explore whether PT-141 for low libido may help men regain sexual desire...","summary":"Clinical discussion noting post-surgery context but no new trial data.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"e38ee0c5739b289b8e4e11c09c118a17d41103a42c1b6989ecb0686cc871f5c4"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/33455598/","title":"The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder","quote":"Bremelanotide may affect female sexual desire by activating presynaptic MC4Rs on neurons in the mPOA of the hypothalamus, leading to increased release of DA.","summary":"Mechanism review detailing CNS action.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"f1b595db88fc864cde3f2e5e4b61bea8677f992b83deb6803e64da671e30b253"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1f9yows/pt141_major_success/","title":"PT-141 Major Success!","quote":"The effect comes on about 2 hours after injection and goes on strongly for at least 18 hours...","summary":"Example anecdotal report of timing and effects.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"63b723640f12cc821fc5128dce68d3fcd78ec5f9ae67932d7634d70e2c6ae3b6"}],"anecdotal_sources":[{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1f9yows/pt141_major_success/","title":"PT-141 Major Success!","quote":"The effect comes on about 2 hours after injection and goes on strongly for at least 18 hours...","summary":"Example anecdotal report of timing and effects.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"63b723640f12cc821fc5128dce68d3fcd78ec5f9ae67932d7634d70e2c6ae3b6"}],"scientific_sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT01382719","title":"Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder","quote":"This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide...","summary":"Phase 3 trial details supporting HSDD efficacy data.","claim_ids":["c1"],"link_status":"ok","quote_status":"unverified","hash":"b37ba9f623c01df7436e68e9bf724e6497f8f74017b8f526eb5785cf8b6decf7"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/33455598/","title":"The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder","quote":"Bremelanotide may affect female sexual desire by activating presynaptic MC4Rs on neurons in the mPOA of the hypothalamus, leading to increased release of DA.","summary":"Mechanism review detailing CNS action.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"f1b595db88fc864cde3f2e5e4b61bea8677f992b83deb6803e64da671e30b253"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"pt-141-post-surgery","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":4,"anecdotal":1,"scientific":2,"user_reports":0,"questions":0,"evidence_ingests":0}}